| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_709fba763c633e67b33088cdac991f07 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 |
| filingDate |
2006-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1282e80e808c2ff80d85451fae248725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63a4b5e5f337bad9ae6e619e26111530
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f377066495554ccf38e7655cae1c2eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_359441dd3f651df5f4eaf0b86a71b08e |
| publicationDate |
2011-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2414241-C2 |
| titleOfInvention |
Drug compositions containing controlled release hypromellose matrixes |
| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention aims at a controlled release composition for an oral solid dosage form. The composition contains mixed hypromellose and polyvinylacetatephthalate. An amount of hypromellose makes 8 to 60 wt %, an amount of polyvinylacetatephthalate is effective for maintaining controlled release of a pharmaceutically active ingredient in vitro and makes 4 to 60 wt % of the mixture. Said mixture of hypromellose and polyvinylacetatephthalate is pressed in a swelling hydrophilic matrix. n EFFECT: invention enables controlled release of the combined pharmaceutically active ingredient. n 25 cl, 6 ex |
| priorityDate |
2005-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |